New AMD drug completes Phase 2 trial
EyePoint

New AMD drug completes Phase 2 trial

EyePoint Pharmaceuticals announced the completion of the Phase 2 trial of their new experimental drug, vorolanib, for the treatment of wet age-related macular degeneration.
Regeneron receives FDA approval for EYLEA HD
diabetic macular edema

Regeneron receives FDA approval for EYLEA HD

The Food and Drug Administraton (FDA) gave approval after two active-controlled, double-masked pivotal trials, which compared EYLEA HD to EYLEA over a 48 week period.

USA Only, Spend $50, get free shipping

Free shipping is currently available for orders within the United States only.